Prof. Carolyn F. Deacon
Carolyn Deacon earned her PhD at the University of Sheffield in the United Kingdom and completed two fellowships in endocrinology, one at the Max-Planck-Institute in Göttingen, Germany, and the other at the University of Sheffield. She then took up a post-doctoral position at the University of Copenhagen in Denmark, supported initially by a Marie Curie fellowship from the European Union, where she obtained her DMSc. She is now senior lecturer in the Department of Biomedical Sciences at the Panum Institute, University of Copenhagen, where she teaches undergraduate dental and medical students and is a supervisor of graduate and postgraduate students. Her current research interests centre on the degradation, metabolism and physiology of the enteropancreatic hormones and the therapeutic applications of incretin hormones, GLP-1 analogues and DPP-4 inhibitors in the treatment of type 2 diabetes and the metabolic syndrome. Early studies investigating the metabolic stability of GLP-1, originating from her laboratory in the mid-1990s, have been instrumental in establishing the principle of using DPP-4 inhibition as a novel antihyperglycaemic therapy. Carolyn Deacon is a member of the steering group of the EASD’s newly formed Incretin Study Group. She has authored more than 200 articles published in peer-reviewed journals (>12 300 citations; author H-index 59 as of Jan 2017), is a regular reviewer for papers submitted to journals in basic sciences, diabetes and endocrinology, and speaks regularly at local, national and international scientific meetings.